# New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome

> **NCT06694363** · — · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 14 (estimated)

## Conditions studied

- Activated PI3K Delta Syndrome

## Interventions

- **BIOLOGICAL:** Blood samples
- **BIOLOGICAL:** Urine samples
- **BIOLOGICAL:** Stool samples

## Key facts

- **NCT ID:** NCT06694363
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-26
- **Primary completion:** 2029-06-27
- **Final completion:** 2029-12-27
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06694363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06694363, "New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT06694363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*